Accelerating the Future Generation of Safe, Efficacious & Accessible Cell Therapies by Harnessing Lessons Learned from Late-Stage Treatments to Develop a Viable Cure for Oncology & Beyond

Thank you to our speakers, sponsors and delegates who joined us in Boston for the summit! If you are interested in the 2024 event, please get in touch at info@hansonwade.com

See all photos from the 8th CAR-TCR Summit 2023 here

“A must-go meeting if you work in cell therapy!”

Erika von Euw, Vice President Discovery and Translational Research, Deverra Therapeutics

Last year was momentous for the cell therapy field: it was the year that CAR-T therapies became CURATIVE.

This decade of success has resulted in explosive investment into the development of CAR and TCR based approaches to ensure more patients around the world can benefit from these lifesaving therapies.  

The 8th CAR-TCR Summit is the industry’s trusted, definitive, end-to-end forum for the global network of autologous and allogeneic cell therapy drug developers. Ensure your whole team stays ahead of the curve with unmatched industry insights shared across discovery through to commercialization.  

The 2023 edition included 3 conference days with 8 content tracks, and an additional 6 deep-dive workshops, bootcamp, focus day, diversity session, C-level think tank and more, with 200+ CAR and TCR experts leading over 1,000 cell therapy peers in discussions that will accelerate pipelines, bringing better drugs to patients faster.  

Who Attended in 2023:

“Good value, relevant content and useful networking with companies
really active and relevant for the space.”
Helen Tayton-Martin, Chief Business Officer, Adaptimmune Therapeutics

CAR-TCR-418
CAR-TCR-38
Partnership Opps (5)

2023 Speakers Included:

“Great speakers with a broad range of experience and lots of time to meet and network.”
Sven Kili, Chief Executive Officer, Antion Biosciences

2023 Lead Partner

2023 Expertise Partners

“Cross-sectional look at the cell therapy industry as a whole. I was impressed from start to finish.”
Damien Fink, Director - Analytical Development, Century Therapeutics